http://www.cnztt.com http://www.cnztt.com/cn/rd-and-science http://www.cnztt.com/cn/rd-and-science/pipelines http://www.cnztt.com/cn/rd-and-science/products-center http://www.cnztt.com/cn/rd-and-science/manufacturing http://www.cnztt.com/cn/investor-relations http://www.cnztt.com/cn/investor-relations/ir-calendar http://www.cnztt.com/cn/career/now-hiring http://www.cnztt.com/cn/about-us/affiliates/akeso-pharma http://www.cnztt.com/cn/about-us/affiliates/ad-pharmaceuticals http://www.cnztt.com/cn/investor-relations/financial-reports http://www.cnztt.com/cn/rd-and-science/rd-platform http://www.cnztt.com/cn/investor-relations/listing-documents http://www.cnztt.com/cn/investor-relations/presentations http://www.cnztt.com/cn/investor-relations/investor-relations-monthly-reports http://www.cnztt.com/cn/investor-relations/announcements-and-circulars http://www.cnztt.com/cn/investor-relations/corporate-governance http://www.cnztt.com/cn/media http://www.cnztt.com/cn/career http://www.cnztt.com/cn/media/akeso-news/20251226 http://www.cnztt.com/cn/media/akeso-news/20251219 http://www.cnztt.com/cn/media/akeso-news/20251218 http://www.cnztt.com/cn/privacy-policy http://www.cnztt.com/en/about-us/contact-us http://www.cnztt.com/hk/investor-relations/presentations http://www.cnztt.com/cn/media/rd-innovation http://www.cnztt.com/en/privacy-policy http://www.cnztt.com/hk/investor-relations/financial-reports http://www.cnztt.com/cn/media/akeso-news http://www.cnztt.com/cn/about-us/affiliates-akeso-pharma http://www.cnztt.com/hk/investor-relations/ir-calendar http://www.cnztt.com/en/media/akeso-news http://www.cnztt.com/cn/about-us/affiliates-akeso-pharma/item-5 http://www.cnztt.com/cn/rd-and-science/products-center/ivonescimab http://www.cnztt.com/cn/rd-and-science/products-center/ebdarokimab http://www.cnztt.com/cn/about-us/affiliates-akeso-pharma/item-1 http://www.cnztt.com/cn/about-us/affiliates-akeso-pharma/item-6 http://www.cnztt.com/hk/investor-relations/announcements-and-circulars http://www.cnztt.com/cn/media/akeso-news/20251118 http://www.cnztt.com/cn/rd-and-science/products-center/cadonilimab http://www.cnztt.com/en/investor-relations/announcements-and-circulars http://www.cnztt.com/en/investor-relations/ir-calendar http://www.cnztt.com/en/investor-relations/financial-reports http://www.cnztt.com/en/rd-and-science/products-center http://www.cnztt.com/en/career/now-hiring http://www.cnztt.com/en/about-us/corporate-profile http://www.cnztt.com/en/about-us/affiliates http://www.cnztt.com/en/about-us/our-vision http://www.cnztt.com/en/rd-and-science/rd-platform http://www.cnztt.com/cn/rd-and-science/products-center/penpulimab http://www.cnztt.com/en http://www.cnztt.com/cn/collaborations http://www.cnztt.com/en/investor-relations/ir-contact http://www.cnztt.com/en/about-us/affiliates/cttq-akesobio http://www.cnztt.com/en/investor-relations/investor-relations-monthly-reports http://www.cnztt.com/en/about-us http://www.cnztt.com/en/collaborations http://www.cnztt.com/en/about-us/management-team http://www.cnztt.com/cn/media/akeso-news/20241104 http://www.cnztt.com/hk/investor-relations/ir-contact http://www.cnztt.com/cn/media/akeso-news/20241105 http://www.cnztt.com/en/investor-relations/presentations http://www.cnztt.com/en/media/akeso-news/250425 http://www.cnztt.com/en/about-us/awards http://www.cnztt.com/en/career http://www.cnztt.com/en/media http://www.cnztt.com/en/media/akeso-news/251030 http://www.cnztt.com/en/media/akeso-news/251117 http://www.cnztt.com/en/media/akeso-news/250923 http://www.cnztt.com/?s=%E5%BC%A0%E5%A4%A9%E7%88%B1%E5%A5%BD%E7%9C%8B&gpc=stf%3D1579320464%2C1581998864%7Cstftype%3D1 http://www.cnztt.com/?s=%E5%9C%86%E7%9C%BC%E5%A5%B3%E6%98%8E%E6%98%9F&gpc=stf%3D1596599849%2C1599278249%7Cstftype%3D1 http://www.cnztt.com/cn/media/akeso-news?page=2 http://www.cnztt.com/?s=%E5%9C%A8%E8%93%9D%E6%B6%A9%E6%97%B6%E5%88%86%E9%A3%9E%E7%BF%94%20%E5%9C%A8%E7%BA%BF&pr=on http://www.cnztt.com/en/media/akeso-news/251103 http://www.cnztt.com/en/media/akeso-news/20251019-1 http://www.cnztt.com/en/media/akeso-news/251110 http://www.cnztt.com/?s=%E5%BC%A0%E5%A4%A9%E7%88%B1%E5%A5%BD%E4%BB%99&gpc=stf%3D1588160030%2C1588764830%7Cstftype%3D1 http://www.cnztt.com/?s=%E5%9B%A0%E4%B8%BA%E5%AE%A0%E7%88%B1&gpc=stf%3D1594459723%2C1597138123%7Cstftype%3D1 http://www.cnztt.com/en/investor-relations http://www.cnztt.com/?s=%E4%BD%A0%E5%A5%BD%E4%B8%96%E7%95%8C&gpc=stf%3D1586099247%2C1588777647%7Cstftype%3D1 http://www.cnztt.com/?s=8%E5%8F%B7%E8%AD%A6%E6%8A%A5&gpc=stf%3D1580372132%2C1580976932%7Cstftype%3D1 http://www.cnztt.com/en/rd-and-science http://www.cnztt.com/en/media/akeso-news/251107-1 http://www.cnztt.com/cn/media/akeso-news?page=7 http://www.cnztt.com/en/investor-relations/corporate-governance http://www.cnztt.com/cn/media/akeso-news/20260211 http://www.cnztt.com/cn/media/akeso-news/20260106 http://www.cnztt.com/?s=%E4%B8%B9%E5%B0%BC%E5%B0%94%E7%9A%84%E8%84%B8&gpc=stf%3D1549357091%2C1580893091%7Cstftype%3D1 http://www.cnztt.com/?s=%E6%97%A0%E9%87%8D%E5%8A%9B%E7%94%B7%E5%AD%90&gpc=stf%3D1580135042%2C1580739842%7Cstftype%3D1 http://www.cnztt.com/cn/about-us/leadership-message http://www.cnztt.com/hk/investor-relations/investor-relations-monthly-reports http://www.cnztt.com/en/rd-and-science/products-center/cadonilimab http://www.cnztt.com/cn/about-us/affiliates-akeso-pharma/item-2 http://www.cnztt.com/cn/about-us/affiliates-akeso-pharma/item-8 http://www.cnztt.com/cn/about-us/affiliates-akeso-pharma/item-9 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma http://www.cnztt.com/cn/about-us/affiliates-akeso-pharma/202411 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/item-2 http://www.cnztt.com/?s=%E5%9C%86%E7%9C%BC%E5%A5%B3%E6%98%8E%E6%98%9F& http://www.cnztt.com/?gpc=stf%3D1580372132%2C1580976932%7Cstftype%3D1&s=8%E5%8F%B7%E8%AD%A6%E6%8A%A5 http://www.cnztt.com/?gpc=stf%3D1586099247%2C1588777647%7Cstftype%3D1&s=%E4%BD%A0%E5%A5%BD%E4%B8%96%E7%95%8C http://www.cnztt.com/cn/media/akeso-news/20260203 http://www.cnztt.com/cn/media/akeso-news/20260130 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/20240926 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/item-4 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/item-6 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/item-7 http://www.cnztt.com/cn/media/akeso-news/20260129 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/202505 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/item-9 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/item-1 http://www.cnztt.com/cn/media/akeso-news/20260123 http://www.cnztt.com/?gpc=stf%3D1579320464%2C1581998864%7Cstftype%3D1&s=%E5%BC%A0%E5%A4%A9%E7%88%B1%E5%A5%BD%E7%9C%8B http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/item-5 http://www.cnztt.com/?gpc=stf%3D1588160030%2C1588764830%7Cstftype%3D1&s=%E5%BC%A0%E5%A4%A9%E7%88%B1%E5%A5%BD%E4%BB%99 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/item10 http://www.cnztt.com/cn/media/akeso-news/20260119 http://www.cnztt.com/?gpc=stf%3D1594459723%2C1597138123%7Cstftype%3D1&s=%E5%9B%A0%E4%B8%BA%E5%AE%A0%E7%88%B1 http://www.cnztt.com/en/about-us/leadership-message http://www.cnztt.com/?gpc=stf%3D1596599849%2C1599278249%7Cstftype%3D1&s=%E5%9C%86%E7%9C%BC%E5%A5%B3%E6%98%8E%E6%98%9F http://www.cnztt.com/cn/media/akeso-news/20260114 http://www.cnztt.com/en/media/akeso-news/260119 http://www.cnztt.com/en/media/akeso-news/260107 http://www.cnztt.com/en/media/akeso-news/260114 http://www.cnztt.com/?pr=on&s=%E5%9C%A8%E8%93%9D%E6%B6%A9%E6%97%B6%E5%88%86%E9%A3%9E%E7%BF%94%20%E5%9C%A8%E7%BA%BF http://www.cnztt.com/cn/media/akeso-news/20250113 http://www.cnztt.com/en/media?page=8 http://www.cnztt.com/en/media/akeso-news/250922 http://www.cnztt.com/?gpc=stf%3D1580135042%2C1580739842%7Cstftype%3D1&s=%E6%97%A0%E9%87%8D%E5%8A%9B%E7%94%B7%E5%AD%90 http://www.cnztt.com/en/media?page=4 http://www.cnztt.com/en/media?page=1 http://www.cnztt.com/en/media?page=2 http://www.cnztt.com/en/media?page=6 http://www.cnztt.com/en/media?page=9 http://www.cnztt.com/en/media/akeso-news/250916 http://www.cnztt.com/en/media?page=5 http://www.cnztt.com/en/media?page=3 http://www.cnztt.com/?gpc=stf%3D1549357091%2C1580893091%7Cstftype%3D1&s=%E4%B8%B9%E5%B0%BC%E5%B0%94%E7%9A%84%E8%84%B8 http://www.cnztt.com/en/media/akeso-news/250915 http://www.cnztt.com/en/media/akeso-news/250910 http://www.cnztt.com/en/media/akeso-news/250907 http://www.cnztt.com/?amp&s=%E5%9C%86%E7%9C%BC%E5%A5%B3%E6%98%8E%E6%98%9F http://www.cnztt.com/en/media/akeso-news/250902 http://www.cnztt.com/cn/about-us/affiliates-akeso-pharma/item-3 http://www.cnztt.com/en/media?page=7 http://www.cnztt.com/en/rd-and-science/manufacturing http://www.cnztt.com/?s=%E7%A5%9E%E7%A7%98%E6%85%88%E5%96%84%E5%AE%B6&gpc=stf%3D1588169040%2C1588773840%7Cstftype%3D1 http://www.cnztt.com/en/about-us/affiliates/akeso-pharma http://www.cnztt.com/cn/media/akeso-news/20251212 http://www.cnztt.com/cn/media/akeso-news?page=6 http://www.cnztt.com/cn/media/akeso-news/20250702 http://www.cnztt.com/cn/media/akeso-news/20250530 http://www.cnztt.com/cn/media/akeso-news?page=3 http://www.cnztt.com/cn/media/akeso-news?page=9 http://www.cnztt.com/?s=%E4%B8%8A%E6%B5%B7%E8%BF%AA%E5%A3%AB%E5%B0%BC%E7%8B%AE%E5%AD%90%E7%8E%8B%E9%97%A8%E7%A5%A8&pn=50 http://www.cnztt.com/en/media/akeso-news/260129 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/item-3 http://www.cnztt.com/en/about-us/affiliates-akeso-pharma/item-8 http://www.cnztt.com/en/about-us/affiliates/ad-pharmaceuticals http://www.cnztt.com/?s=%E5%9C%86%E7%9C%BC%E5%A5%B3%E6%98%8E%E6%98%9F& http://www.cnztt.com/asax. http://www.cnztt.com/cn/about-us/affiliates-ad-pharma http://www.cnztt.com/cn/media/akeso-news/20251125 http://www.cnztt.com/cn/media/rd-innovation/2019-06-29 http://www.cnztt.com/cn/media/rd-innovation/2020-06-24 http://www.cnztt.com/cn/media/rd-innovation/2020-06-02 http://www.cnztt.com/cn/media/akeso-news/20251209-1 http://www.cnztt.com/cn/career/meet-our-people http://www.cnztt.com/en/media/akeso-news/250426 http://www.cnztt.com/?s=%E6%97%A0%E9%87%8D%E5%8A%9B%E7%94%B7%E5%AD%90&gpc=stf=1580135042,1580739842%7Cstftype=1 http://www.cnztt.com/cn/about-us/affiliates-akeso-pharma/202505 http://www.cnztt.com/en/media/akeso-news/251209 http://www.cnztt.com/cn/media/akeso-news/20250703 http://www.cnztt.com/cn/media/akeso-news/20250708 http://www.cnztt.com/cn/media/rd-innovation/2018-11-30 http://www.cnztt.com/cn/media/akeso-news/20250710 http://www.cnztt.com/cn/media/akeso-news/20250626 http://www.cnztt.com/?s=%E5%9C%86%E7%9C%BC%E5%A5%B3%E6%98%8E%E6%98%9F http://www.cnztt.com/en/media/akeso-news/250828 http://www.cnztt.com/cn/media/rd-innovation/2019-04-02 http://www.cnztt.com/en/media/akeso-news/250423 http://www.cnztt.com/en/media/akeso-news/250418 http://www.cnztt.com/en/media/akeso-news/250428 http://www.cnztt.com/en/about-us/affiliates-ad-pharma http://www.cnztt.com/en/media/akeso-news/250331 http://www.cnztt.com/en/media/akeso-news/250508 http://www.cnztt.com/en/career/meet-our-people http://www.cnztt.com/en/media/akeso-news/250321 http://www.cnztt.com/en/media/akeso-news/250605 http://www.cnztt.com/en/about-us/affiliates-ad-pharma/patient-enrollment-was-completed-ahead-of-schedule-for-the-key-registered-phase-iii-clinical-trial-of-ebronucimab-in http://www.cnztt.com/en/about-us/affiliates-ad-pharma/the-phase-ii-clinical-study-of-ebronucimab-in-the-treatment-of-hypercholesterolemia-patients-at-high-risk-or http://www.cnztt.com/en/about-us/affiliates-ad-pharma/the-first-patient-was-enrolled-in-the-phase-ii-clinical-trial-of-ebronucimab-in-the-treatment-of-heterozygous-familial-hypercholesterolemia http://www.cnztt.com/en/about-us/affiliates-ad-pharma/the-phase-ii-clinical-results-of-ebronucimab-in http://www.cnztt.com/en/about-us/affiliates-ad-pharma/phase-iil-clinical-results-of-ebronucimab-in-chinese-patients http://www.cnztt.com/en/about-us/affiliates-ad-pharma/patient-enrollment-was-completed-ahead-of-schedule-for http://www.cnztt.com/en/about-us/affiliates-ad-pharma/the-patient-enrollment-was-completed-in-the-registered-clinical-study-of-ebronucimab-in-the-treatment-of-heterozygous-familial-hypercholesterolemia http://www.cnztt.com/en/media/akeso-news/20250317 http://www.cnztt.com/en/media/akeso-news/250616 http://www.cnztt.com/en/media/akeso-news/250306 http://www.cnztt.com/en/media/akeso-news/250703 http://www.cnztt.com/en/about-us/affiliates-ad-pharma/nmpa-accepted-ebronucimab-pcsk9-marketing-application-in-two-indications-1-primary-hyperchol http://www.cnztt.com/en/media/akeso-news/250227 http://www.cnztt.com/en/media/akeso-news/250307 http://www.cnztt.com/en/media/akeso-news/250716 http://www.cnztt.com/?gpc=stf%3D1588169040%2C1588773840%7Cstftype%3D1&s=%E7%A5%9E%E7%A7%98%E6%85%88%E5%96%84%E5%AE%B6 http://www.cnztt.com/en/media/akeso-news/250728 http://www.cnztt.com/en/media/akeso-news/250225 http://www.cnztt.com/?pn=50&s=%E4%B8%8A%E6%B5%B7%E8%BF%AA%E5%A3%AB%E5%B0%BC%E7%8B%AE%E5%AD%90%E7%8E%8B%E9%97%A8%E7%A5%A8 http://www.cnztt.com/en/media/akeso-news/250731 http://www.cnztt.com/en/media/akeso-news/250804 http://www.cnztt.com/en/media/akeso-news/250811 http://www.cnztt.com/en/media/akeso-news/250820 http://www.cnztt.com/en/media/monthly-news http://www.cnztt.com/en/about-us/affiliates-ad-pharma/ebronucimab-was-first-approved-in-china-to-initiate-clinical-trials-for-the-treatment-of-hyperlipidemia http://www.cnztt.com/cn/media/akeso-news/20250624 http://www.cnztt.com/?s=%E5%BC%A0%E5%A4%A9%E7%88%B1%E5%A5%BD%E7%9C%8B http://www.cnztt.com/cn/media?page=2 http://www.cnztt.com/cn/media?page=3 http://www.cnztt.com/cn/media?page=4 http://www.cnztt.com/cn/media?page=5 http://www.cnztt.com/cn/media?page=6 http://www.cnztt.com/cn/media?page=7 http://www.cnztt.com/cn/media?page=8 http://www.cnztt.com/cn/media?page=9 http://www.cnztt.com/cn/media/akeso-news/20251117 http://www.cnztt.com/cn/media/akeso-news/20251207 http://www.cnztt.com/cn/media/akeso-news/20251209 http://www.cnztt.com/cn/media/akeso-news/20251211 http://www.cnztt.com/cn/media/akeso-news?page=10 http://www.cnztt.com/?s=%E5%BC%A0%E5%A4%A9%E7%88%B1%E5%A5%BD%E4%BB%99&gpc=stf=1588160030,1588764830%7Cstftype=1 http://www.cnztt.com/cn/media/akeso-news/20250225 http://www.cnztt.com/cn/media/akeso-news/20250214 http://www.cnztt.com/cn/media/akeso-news/20260105 http://www.cnztt.com/cn/media/akeso-news/20250227 http://www.cnztt.com/cn/media/akeso-news/20250314 http://www.cnztt.com/cn/media/akeso-news/20250226 http://www.cnztt.com/cn/media/akeso-news/20250206 http://www.cnztt.com/cn/media/akeso-news/20250210 http://www.cnztt.com/cn/media/akeso-news/20250313 http://www.cnztt.com/cn/media/akeso-news/20250213 http://www.cnztt.com/cn/media/akeso-news/20250307 http://www.cnztt.com/cn/media/akeso-news/20250306 http://www.cnztt.com/cn/media/akeso-news/20250205 http://www.cnztt.com/cn/media/akeso-news/20250127 http://www.cnztt.com/cn/media/akeso-news?page=12 http://www.cnztt.com/cn/media/akeso-news?page=13 http://www.cnztt.com/cn/media/akeso-news/20250123 http://www.cnztt.com/en/about-us/affiliates-ad-pharma/phase-iil-clinical-results-of-ebronucimab-were-published-at-the-european-atherosclerosis-society-eas-2023 http://www.cnztt.com/cn/media/akeso-news/20241202 http://www.cnztt.com/cn/media/akeso-news/20241206 http://www.cnztt.com/cn/media/akeso-news/20241211 http://www.cnztt.com/cn/media/akeso-news/20241205 http://www.cnztt.com/cn/media/akeso-news/20241111 http://www.cnztt.com/cn/media/akeso-news/20241126 http://www.cnztt.com/cn/media/akeso-news/20241129 http://www.cnztt.com/cn/media/akeso-news/20241108 http://www.cnztt.com/cn/media/akeso-news/20241203 http://www.cnztt.com/cn/media/akeso-news/20241107 http://www.cnztt.com/cn/media/akeso-news/20241120 http://www.cnztt.com/cn/media/akeso-news/20241217 http://www.cnztt.com/cn/media/akeso-news/20241204 http://www.cnztt.com/cn/media/akeso-news/20241031 http://www.cnztt.com/cn/media/akeso-news/20241121 http://www.cnztt.com/cn/media/akeso-news/20250109 http://www.cnztt.com/cn/media/akeso-news/20241122 http://www.cnztt.com/cn/media/akeso-news/20241219 http://www.cnztt.com/cn/media/akeso-news/20241030 http://www.cnztt.com/cn/media/akeso-news/20250107 http://www.cnztt.com/cn/media/akeso-news/20251110 http://www.cnztt.com/cn/media/akeso-news/20241119 http://www.cnztt.com/cn/media/akeso-news/20241220 http://www.cnztt.com/cn/media/akeso-news/20241029 http://www.cnztt.com/cn/media/akeso-news/20241231 http://www.cnztt.com/cn/media/akeso-news/20251107-1 http://www.cnztt.com/cn/media/akeso-news/20241224 http://www.cnztt.com/cn/media/akeso-news/20241028 http://www.cnztt.com/cn/media/akeso-news/20241227 http://www.cnztt.com/cn/media/akeso-news/20251107 http://www.cnztt.com/cn/media/akeso-news/20250623 http://www.cnztt.com/cn/media/akeso-news/20241225 http://www.cnztt.com/cn/media/akeso-news/20241022 http://www.cnztt.com/cn/media/akeso-news/20241226 http://www.cnztt.com/cn/media/akeso-news/20251106 http://www.cnztt.com/cn/media/akeso-news/20250620 http://www.cnztt.com/cn/media/akeso-news/20241016 http://www.cnztt.com/cn/media/akeso-news/20251104 http://www.cnztt.com/cn/media/akeso-news/20250619 http://www.cnztt.com/cn/media/akeso-news/20241014-1 http://www.cnztt.com/cn/media/akeso-news/20251103 http://www.cnztt.com/cn/media/akeso-news/20250616 http://www.cnztt.com/cn/media/akeso-news/20251022 http://www.cnztt.com/cn/media/akeso-news/20240815 http://www.cnztt.com/cn/media/akeso-news/20240821 http://www.cnztt.com/cn/media/akeso-news/20250617 http://www.cnztt.com/cn/media/akeso-news/20240812 http://www.cnztt.com/en/media/akeso-news/250214 http://www.cnztt.com/cn/media/akeso-news/20241014 http://www.cnztt.com/cn/media/akeso-news/20251030 http://www.cnztt.com/en/media/akeso-news/250213 http://www.cnztt.com/cn/media/akeso-news/20241012 http://www.cnztt.com/cn/media/akeso-news/20251024 http://www.cnztt.com/cn/media/akeso-news/20250605 http://www.cnztt.com/cn/media/akeso-news/20241010 http://www.cnztt.com/cn/media/akeso-news?page=14 http://www.cnztt.com/cn/media/akeso-news/20240820 http://www.cnztt.com/cn/media/akeso-news/20241011 http://www.cnztt.com/cn/media/akeso-news/20240829 http://www.cnztt.com/en/media/akeso-news/250205 http://www.cnztt.com/cn/media/akeso-news/20251021 http://www.cnztt.com/cn/media/akeso-news/20251020-3 http://www.cnztt.com/cn/media/akeso-news/20250513 http://www.cnztt.com/cn/media/akeso-news/20250428 http://www.cnztt.com/cn/media/akeso-news/20250516 http://www.cnztt.com/en/media/akeso-news/250127 http://www.cnztt.com/cn/media/akeso-news/20250514 http://www.cnztt.com/en/media/akeso-news/250123 http://www.cnztt.com/cn/media/akeso-news/20251020-2 http://www.cnztt.com/en/investor-relations/financial-calendar http://www.cnztt.com/en/media/akeso-news/241204 http://www.cnztt.com/cn/media/akeso-news/20251020 http://www.cnztt.com/cn/media/akeso-news/20251016 http://www.cnztt.com/en/media/akeso-news/akeso-biopharma-to-attend-jefferies-london-healthcare-conference-and-morgan-stanley-23rd-asia-pacific-summit http://www.cnztt.com/cn/media/akeso-news/2025929 http://www.cnztt.com/cn/media/akeso-news/20250509 http://www.cnztt.com/cn/media/akeso-news/20250922 http://www.cnztt.com/en/media/akeso-news/241129 http://www.cnztt.com/cn/media/akeso-news/20251018 http://www.cnztt.com/cn/media/akeso-news/20240729 http://www.cnztt.com/cn/media/akeso-news/20250508 http://www.cnztt.com/cn/media/akeso-news/20250425 http://www.cnztt.com/en/media/akeso-news/20241128 http://www.cnztt.com/cn/media/akeso-news/20250507 http://www.cnztt.com/?gpc=stf=1588160030,1588764830%7Cstftype=1&s=%E5%BC%A0%E5%A4%A9%E7%88%B1%E5%A5%BD%E4%BB%99 http://www.cnztt.com/en/media/akeso-news/akesos-penpulimab-combination-therapy-for-first-line-treatment-of-hepatocellular-carcinoma-accepted-by-nmpa http://www.cnztt.com/cn/media/akeso-news/20240822 http://www.cnztt.com/cn/media/akeso-news/20251010 http://www.cnztt.com/cn/media/akeso-news/20250430 http://www.cnztt.com/cn/media/akeso-news?page=16 http://www.cnztt.com/cn/media/akeso-news/20250925 http://www.cnztt.com/cn/media/akeso-news/20250426 http://www.cnztt.com/cn/media/akeso-news/20240829-1 http://www.cnztt.com/cn/media/akeso-news/20240816 http://www.cnztt.com/cn/media/akeso-news/20240730 http://www.cnztt.com/cn/media/akeso-news/20240805 http://www.cnztt.com/cn/media/akeso-news/20241002-1 http://www.cnztt.com/cn/media/akeso-news/20241002 http://www.cnztt.com/cn/media/akeso-news/20250923 http://www.cnztt.com/cn/media/akeso-news/20240807 http://www.cnztt.com/cn/media/akeso-news/20241001 http://www.cnztt.com/cn/media/akeso-news/20250423 http://www.cnztt.com/cn/media/akeso-news/20240902 http://www.cnztt.com/cn/media/akeso-news/20240724 http://www.cnztt.com/cn/media/akeso-news/20250918 http://www.cnztt.com/cn/media/akeso-news/20250421-1 http://www.cnztt.com/cn/media/akeso-news/20240723-2 http://www.cnztt.com/cn/media/akeso-news/20250916 http://www.cnztt.com/cn/media/akeso-news/20250421 http://www.cnztt.com/cn/media/akeso-news/20240723-1 http://www.cnztt.com/cn/media/akeso-news/20250915 http://www.cnztt.com/en/media/akeso-news/241101 http://www.cnztt.com/en/media/akeso-news/241031 http://www.cnztt.com/cn/media/akeso-news/20250410 http://www.cnztt.com/cn/media/akeso-news/20240506 http://www.cnztt.com/cn/media/akeso-news/20250325 http://www.cnztt.com/cn/media/akeso-news/20250418 http://www.cnztt.com/en/media/akeso-news/20241108 http://www.cnztt.com/cn/media/akeso-news/20240723 http://www.cnztt.com/cn/media/akeso-news/20250910 http://www.cnztt.com/cn/media/akeso-news/20250416 http://www.cnztt.com/cn/media/akeso-news/20240716 http://www.cnztt.com/cn/media/akeso-news/20250907 http://www.cnztt.com/cn/media/akeso-news/20250411 http://www.cnztt.com/cn/media/akeso-news/20240603 http://www.cnztt.com/en/media/akeso-news/akeso-s-ebronucimab-pcsk9-approved-for-two-indications-for-the-treatment-of-hypercholesterolemia-in-china http://www.cnztt.com/cn/media/akeso-news/20240612 http://www.cnztt.com/cn/media/akeso-news/20250905 http://www.cnztt.com/en/media/akeso-news/241028 http://www.cnztt.com/cn/media/akeso-news/240607 http://www.cnztt.com/cn/media/akeso-news/20250904 http://www.cnztt.com/cn/media/akeso-news/20250403 http://www.cnztt.com/en/media/akeso-news/241016 http://www.cnztt.com/cn/media/akeso-news/20250902 http://www.cnztt.com/cn/media/akeso-news/20250331-1 http://www.cnztt.com/en/media/akeso-news/akeso-secures-250-million-usd-to-propel-global-expansion-of-its-innovative-drug-pipeline http://www.cnztt.com/cn/media/akeso-news/20240601 http://www.cnztt.com/cn/media/akeso-news?page=19 http://www.cnztt.com/cn/media/akeso-news/240524-1 http://www.cnztt.com/cn/media/akeso-news/20250811 http://www.cnztt.com/cn/media/akeso-news?page=18 http://www.cnztt.com/cn/media/akeso-news/20250829 http://www.cnztt.com/cn/media/akeso-news/20250331 http://www.cnztt.com/cn/media/akeso-news/240116 http://www.cnztt.com/cn/media/akeso-news/20250321 http://www.cnztt.com/cn/media/akeso-news/20250821 http://www.cnztt.com/cn/media/akeso-news/20250814-1 http://www.cnztt.com/cn/media/akeso-news/2340531 http://www.cnztt.com/cn/media/akeso-news/240205 http://www.cnztt.com/cn/media/akeso-news/240425 http://www.cnztt.com/cn/media/akeso-news/20250806 http://www.cnztt.com/cn/media/akeso-news/231024 http://www.cnztt.com/cn/media/akeso-news/231204 http://www.cnztt.com/cn/media/akeso-news?page=17 http://www.cnztt.com/cn/media/akeso-news/20250828-1 http://www.cnztt.com/cn/media/akeso-news/20240430-1 http://www.cnztt.com/cn/media/akeso-news/240129 http://www.cnztt.com/cn/media/akeso-news/240423 http://www.cnztt.com/cn/media/akeso-news/240301 http://www.cnztt.com/cn/media/akeso-news/240412 http://www.cnztt.com/cn/media/akeso-news/20250828 http://www.cnztt.com/cn/media/akeso-news/20250825-1 http://www.cnztt.com/cn/media/akeso-news/240305 http://www.cnztt.com/cn/media/akeso-news/240306 http://www.cnztt.com/cn/media/akeso-news/231227 http://www.cnztt.com/cn/media/akeso-news/231106 http://www.cnztt.com/cn/media/akeso-news/240325 http://www.cnztt.com/cn/media/akeso-news/240429 http://www.cnztt.com/cn/media/akeso-news/240319 http://www.cnztt.com/cn/media/akeso-news/240424 http://www.cnztt.com/cn/media/akeso-news/240524 http://www.cnztt.com/cn/media/akeso-news/240327 http://www.cnztt.com/cn/media/akeso-news/20250814 http://www.cnztt.com/cn/media/akeso-news/240123 http://www.cnztt.com/cn/media/akeso-news/240308 http://www.cnztt.com/cn/media/akeso-news/20250827 http://www.cnztt.com/en/media/akeso-news/240908 http://www.cnztt.com/cn/media/akeso-news/240408 http://www.cnztt.com/cn/media/akeso-news/20240531 http://www.cnztt.com/cn/media/akeso-news/20250820 http://www.cnztt.com/cn/media/akeso-news?page=20 http://www.cnztt.com/cn/media/akeso-news/20231023 http://www.cnztt.com/cn/media/akeso-news/231025 http://www.cnztt.com/cn/media/akeso-news/20240430 http://www.cnztt.com/cn/media/akeso-news/20240227 http://www.cnztt.com/cn/media/akeso-news/20250328 http://www.cnztt.com/cn/media/akeso-news/20240209 http://www.cnztt.com/cn/media/akeso-news/20240104 http://www.cnztt.com/cn/media/akeso-news?page=22 http://www.cnztt.com/cn/media/akeso-news/241015 http://www.cnztt.com/cn/media/akeso-news/240109 http://www.cnztt.com/cn/media/akeso-news/231120 http://www.cnztt.com/cn/media/akeso-news/240105 http://www.cnztt.com/en/media/akeso-news/akesos-cadonilimab-receives-second-indication-approval-from-nmpa-for-first-line-treatment-of-gastricgej-cancer http://www.cnztt.com/cn/media/akeso-news/20250825 http://www.cnztt.com/cn/media/akeso-news/240319-1 http://www.cnztt.com/en/media/akeso-news/240918-2 http://www.cnztt.com/en/media/akeso-news/240918-1 http://www.cnztt.com/en/media/akeso-news/240918 http://www.cnztt.com/en/media/akeso-news/250909 http://www.cnztt.com/cn/media/akeso-news/231211 http://www.cnztt.com/cn/media/akeso-news/20250804 http://www.cnztt.com/cn/media/akeso-news?page=21 http://www.cnztt.com/cn/media/akeso-news/20250731 http://www.cnztt.com/en/media/akeso-news/240906 http://www.cnztt.com/cn/media/akeso-news/231013 http://www.cnztt.com/cn/media/akeso-news/231205 http://www.cnztt.com/cn/media/akeso-news/231127 http://www.cnztt.com/cn/media/akeso-news/231214 http://www.cnztt.com/cn/media/akeso-news/231012 http://www.cnztt.com/cn/media/akeso-news/231019 http://www.cnztt.com/cn/media/akeso-news/231103 http://www.cnztt.com/cn/media/akeso-news/231101 http://www.cnztt.com/cn/media/akeso-news/230926 http://www.cnztt.com/cn/media/akeso-news/231011 http://www.cnztt.com/cn/media/akeso-news/231030 http://www.cnztt.com/cn/media/akeso-news/231201 http://www.cnztt.com/cn/media/akeso-news/231213 http://www.cnztt.com/cn/media/akeso-news/231123 http://www.cnztt.com/cn/media/akeso-news/230928 http://www.cnztt.com/cn/media/akeso-news/231107 http://www.cnztt.com/cn/media/akeso-news/231116 http://www.cnztt.com/cn/media/akeso-news/230925 http://www.cnztt.com/cn/media/akeso-news/230806 http://www.cnztt.com/cn/media/akeso-news/20250728 http://www.cnztt.com/cn/media/akeso-news/230918 http://www.cnztt.com/cn/media/akeso-news/230731 http://www.cnztt.com/cn/media/akeso-news/230818 http://www.cnztt.com/cn/media/akeso-news/20250725 http://www.cnztt.com/cn/media/akeso-news/20221114 http://www.cnztt.com/cn/media/akeso-news/230912 http://www.cnztt.com/cn/media/akeso-news/230727 http://www.cnztt.com/cn/media/akeso-news/230821 http://www.cnztt.com/en/media/akeso-news/240829 http://www.cnztt.com/cn/media/akeso-news/20250724 http://www.cnztt.com/cn/media/akeso-news/230911 http://www.cnztt.com/cn/media/akeso-news/20221104 http://www.cnztt.com/cn/media/akeso-news/230704 http://www.cnztt.com/cn/media/akeso-news/230823 http://www.cnztt.com/cn/media/akeso-news/230505 http://www.cnztt.com/cn/media/akeso-news/20220621 http://www.cnztt.com/cn/media/akeso-news/20221115 http://www.cnztt.com/cn/media/akeso-news/230703 http://www.cnztt.com/cn/media/akeso-news/20230606-3 http://www.cnztt.com/cn/media/akeso-news/230220 http://www.cnztt.com/cn/media/akeso-news/20250723 http://www.cnztt.com/en/media/akeso-news/240815 http://www.cnztt.com/cn/media/akeso-news/230904 http://www.cnztt.com/cn/media/akeso-news/230824 http://www.cnztt.com/cn/media/akeso-news/20221101 http://www.cnztt.com/cn/media/akeso-news/20221021 http://www.cnztt.com/cn/media/akeso-news/20220902 http://www.cnztt.com/en/media/akeso-news/240806